HIV-related pulmonary arterial hypertension;L'hypertension artérielle pulmonaire associée au VIH

Revue des Maladies Respiratoires

Volumn 29, Issue 4, 2012, Pages 491-500

  Savale, L ^a,b,c   Lador, F ^b,d   Jais, X ^a,b,c   Montani, D ^a,b,c   Simonneau, G ^a,b,c   Humbert, M ^a,b,c   Sitbon, O ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Universite Paris Sud   (France)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

HIV; Pulmonary arterial hypertension; Treatment

Indexed keywords

BOSENTAN; PROSTACYCLIN;

DRUG EFFICACY; DYSPNEA; HEART CATHETERIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PULMONARY HYPERTENSION; REVIEW; SCREENING; SURVIVAL;

EID: 84863610753     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2011.09.050     Document Type: Review

References (38)

1. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987;18:1293-6. (Pubitemid 18018963)
2. Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-71.
3. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-5.
4. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-13.
5. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008;22:S35-40.
6. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30.
7. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-9. (Pubitemid 36609730)
8. Mehta NJ, Khan IA, Mehta RN, et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-41.
9. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67-75.
10. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994;89:2722-7. (Pubitemid 24173693)
11. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997;28:434-42. (Pubitemid 27175084)
12. Mesa RA, Edell ES, Dunn WF, et al. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73: 37-45. (Pubitemid 28063644)
13. Escamilla R, Hermant C, Berjaud J, et al. Pulmonary venoocclusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995;8:1982-4.
14. Heron E, Laaban JP, Capron F, et al. Thrombotic primary pulmonary hypertension in an HIV+ patient. Eur Heart J 1994;15:394-6. (Pubitemid 24127385)
15. Ruchelli ED, Nojadera G, Rutstein RM, et al. Pulmonary venoocclusive disease. Another vascular disorder associated with human immunodeficiency virus infection? Arch Pathol Lab Med 1994;118:664-6. (Pubitemid 24173630)
16. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 2008;22:S41-7.
17. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9. (Pubitemid 28194842)
18. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145:1196-200.
19. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV- 1 glycoprotein 120. J Immunol 1993;150:4601-9. (Pubitemid 23133737)
20. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002;5:141-51. (Pubitemid 36687517)
21. Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-45. (Pubitemid 44223125)
22. Valmary S, Dorfmuller P, Montani D, et al. Human gammaherpesviruses EBV and HHV-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest 2010.
23. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003;349:1113-22. (Pubitemid 37122323)
24. Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996;153:1299-301.
25. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63.
26. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:1898-907.
27. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-50.
28. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170: 1212-7. (Pubitemid 39577380)
29. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-8.
30. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIVrelated pulmonary hypertension. AIDS 2001;15:1747-8.
31. Alp S, Schlottmann R, Bauer TT, et al. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003;17:1714-5. (Pubitemid 36951701)
32. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999;13:F101-7. (Pubitemid 29509575)
33. Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107. (Pubitemid 30612027)
34. Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-4. (Pubitemid 30447185)
35. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-85. (Pubitemid 38951268)
36. Hebert VY, Crenshaw BL, Romanoff RL, et al. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 2004;4:117-31. (Pubitemid 39310746)
37. Zinkernagel AS, von Overbeck J, Opravil M, et al. Long-term survival and interruption of HAART in HIV-related pulmonary hypertension. Eur J Clin Microbiol Infect Dis 2005;24: 153-5. (Pubitemid 40487387)
38. Gary-Bobo G, Houssaini A, Amsellem V, et al. Effects of HIV protease inhibitors on progression of monocrotaline-and hypoxia-induced pulmonary hypertension in rats. Circulation 2010;122:1937-47.